GlassScriptPhysician profile
Elizabeth Head
NPI 1811729478
$1,712.85
in general payments reported to CMS, 2019-2025
27 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $433 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $302.27 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $285.41 | 2024-2025 | |
| Lilly USA, LLC | $105.73 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $95.06 | 2025 | Erleada, Talvey, Darzalex |
| Eisai INC. | $92.00 | 2024-2025 | |
| Novo Nordisk INC | $86.75 | 2025 | Ozempic |
| Servier Pharmaceuticals LLC | $77.70 | 2024-2025 | |
| Geron Corporation | $76.87 | 2025 | Rytelo |
| Abbvie INC. | $71.63 | 2025 | |
| Jazz Pharmaceuticals INC. | $56.92 | 2024-2025 | |
| Daiichi Sankyo INC. | $51.12 | 2025 | Enhertu, Datroway |
| Syndax Pharmaceuticals, INC. | $50.34 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals LP | $47.31 | 2024-2025 | Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $40.56 | 2025 | Fruzaqla |
| Caris Mpi, INC. | $33.07 | 2025 | Mi Cancer Seek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $30.52 | 2024 | Epkinly, Tivdak |
| Pharmacosmos Therapeutics INC. | $28.18 | 2025 | Monoferric |
| Acrotech Biopharma INC. | $25.55 | 2025 | Beleodaq |
| Exelixis INC. | $22.34 | 2024 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $21.70 | 2024 | |
| Shield Therapeutics INC | $17.79 | 2025 | |
| Glaxosmithkline, LLC. | $17.73 | 2025 | Zejula, Jemperli |
| Beigene USA, INC. | $17.09 | 2024 | Brukinsa |
| Beone Medicines USA, INC. | $16.51 | 2025 | Brukinsa |
| Genentech USA, INC. | $15.17 | 2025 | Columvi, Itovebi, Lunsumio |
| Recordati_rare_diseases_inc. | $14.07 | 2025 | Sylvant |
| Legend Biotech USA INC. | $13.46 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.